Brief: Cocrystal Pharma’s Covid-19 Oral, Intranasal/Pulmonary Protease Inhibitors Exhibit Powerful In Vitro Potency Against The Sars-Cov-2 Omicron Variant
22/12/2021 13:02
Dec 22 (Reuters) - Cocrystal Pharma Inc COCP.O :
* COCRYSTAL PHARMA’S COVID-19 ORAL AND INTRANASAL/PULMONARY
PROTEASE INHIBITORS EXHIBIT POWERFUL IN VITRO POTENCY AGAINST
THE SARS-COV-2 OMICRON VARIANT
Source text for Eikon: ID:nGNX1FBvsH
Further company coverage: COCP.O
Recent news on Cocrystal Pharma
See all newsBrief: Cocrystal Pharma Announces Last Subject Dosed In Phase 1b Human Challenge Study Evaluating CDI-988 For Norovirus Prevention And Treatment
Cocrystal Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Cocrystal Pharma Inc expected to post a loss of 16 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Medtronic, Macy's, USA Rare Earth
U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway